These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 29760693)

  • 1. Treatment Intensification in HIV-Infected Patients Is Associated With Reduced Frequencies of Regulatory T Cells.
    Grützner EM; Hoffmann T; Wolf E; Gersbacher E; Neizert A; Stirner R; Pauli R; Ulmer A; Brust J; Bogner JR; Jaeger H; Draenert R
    Front Immunol; 2018; 9():811. PubMed ID: 29760693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid-Derived Suppressor Cells Associated With Disease Progression in Primary HIV Infection: PD-L1 Blockade Attenuates Inhibition.
    Zhang ZN; Yi N; Zhang TW; Zhang LL; Wu X; Liu M; Fu YJ; He SJ; Jiang YJ; Ding HB; Chu ZX; Shang H
    J Acquir Immune Defic Syndr; 2017 Oct; 76(2):200-208. PubMed ID: 28570288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
    Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
    AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved CD4 T cell profile in HIV-infected subjects on maraviroc-containing therapy is associated with better responsiveness to HBV vaccination.
    Herrero-Fernández I; Rosado-Sánchez I; Genebat M; Tarancón-Díez L; Rodríguez-Méndez MM; Pozo-Balado MM; Lozano C; Ruiz-Mateos E; Leal M; Pacheco YM
    J Transl Med; 2018 Aug; 16(1):238. PubMed ID: 30157873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART.
    Macatangay BJ; Szajnik ME; Whiteside TL; Riddler SA; Rinaldo CR
    PLoS One; 2010 Mar; 5(3):e9852. PubMed ID: 20352042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells.
    Vollbrecht T; Stirner R; Tufman A; Roider J; Huber RM; Bogner JR; Lechner A; Bourquin C; Draenert R
    AIDS; 2012 Jul; 26(12):F31-7. PubMed ID: 22526518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Significance of Myeloid-Derived Suppressor Cells in Human Immunodeficiency Virus-1/ Hepatitis C Virus-coinfected Patients.
    Lei AH; Yang Q; Cai WP; Liu YF; Lan Y; Qin AP; Hu FY; Zhou J
    Scand J Immunol; 2016 Jun; 83(6):438-44. PubMed ID: 26972443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients.
    Papasavvas E; Foulkes A; Yin X; Joseph J; Ross B; Azzoni L; Kostman JR; Mounzer K; Shull J; Montaner LJ
    Immunology; 2015 Jul; 145(3):380-90. PubMed ID: 25684333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
    Llibre JM; Buzón MJ; Massanella M; Esteve A; Dahl V; Puertas MC; Domingo P; Gatell JM; Larrouse M; Gutierrez M; Palmer S; Stevenson M; Blanco J; Martinez-Picado J; Clotet B
    Antivir Ther; 2012; 17(2):355-64. PubMed ID: 22290239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.
    Hey-Cunningham WJ; Murray JM; Natarajan V; Amin J; Moore CL; Emery S; Cooper DA; Zaunders J; Kelleher AD; Koelsch KK;
    AIDS; 2015 May; 29(8):911-9. PubMed ID: 25730509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of antiretroviral and tuberculosis therapies on CD4
    Chiacchio T; Petruccioli E; Vanini V; Cuzzi G; La Manna MP; Orlando V; Pinnetti C; Sampaolesi A; Antinori A; Caccamo N; Goletti D
    Immunol Lett; 2018 Jun; 198():33-43. PubMed ID: 29635002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.
    Chen HM; Ma G; Gildener-Leapman N; Eisenstein S; Coakley BA; Ozao J; Mandeli J; Divino C; Schwartz M; Sung M; Ferris R; Kao J; Wang LH; Pan PY; Ko EC; Chen SH
    Clin Cancer Res; 2015 Sep; 21(18):4073-4085. PubMed ID: 25922428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the dysregulation between regulatory B and T cells (Breg and Treg) in human immunodeficiency virus (HIV)-infected patients.
    Gutiérrez C; Lopez-Abente J; Pérez-Fernández V; Prieto-Sánchez A; Correa-Rocha R; Moreno-Guillen S; Muñoz-Fernández MÁ; Pion M
    PLoS One; 2019; 14(3):e0213744. PubMed ID: 30917149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy.
    Negredo E; Massanella M; Puertas MC; Buzón MJ; Puig J; Pérez-Alvárez N; Pérez-Santiago J; Bonjoch A; Moltó J; Jou A; Echeverría P; Llibre JM; Martínez-Picado J; Clotet B; Blanco J
    J Antimicrob Chemother; 2013 Oct; 68(10):2358-62. PubMed ID: 23677919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.
    Vallejo A; Gutierrez C; Hernandez-Novoa B; Diaz L; Madrid N; Abad-Fernandez M; Dronda F; Perez-Elias MJ; Zamora J; Muñoz E; Muñoz-Fernandez MA; Moreno S
    AIDS; 2012 Sep; 26(15):1885-94. PubMed ID: 22992577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe immune dysregulation affects CD4⁺CD25(hi)FoxP3⁺ regulatory T cells in HIV-infected patients with low-level CD4 T-cell repopulation despite suppressive highly active antiretroviral therapy.
    Méndez-Lagares G; Pozo-Balado MM; Genebat M; García Pergañeda A; Leal M; Pacheco YM
    J Infect Dis; 2012 May; 205(10):1501-9. PubMed ID: 22457273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired Th17 polarization of phenotypically naive CD4(+) T-cells during chronic HIV-1 infection and potential restoration with early ART.
    DaFonseca S; Niessl J; Pouvreau S; Wacleche VS; Gosselin A; Cleret-Buhot A; Bernard N; Tremblay C; Jenabian MA; Routy JP; Ancuta P
    Retrovirology; 2015 Apr; 12():38. PubMed ID: 25924895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression.
    Zhang JC; Zhang HJ; Li Y; Jing D; Liu Q; Zhao K; Liu QQ; Zhuang Y; Kang WZ; Sun YT
    Scand J Infect Dis; 2013 May; 45(5):368-77. PubMed ID: 23186319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with an HIV-1 immunogen induces CD4+ and CD8+ HIV-1-specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy.
    Valor L; Navarro J; Carbone J; Rodríguez-Sáinz C; Gil J; López F; Fernández-Cruz E;
    Vaccine; 2008 May; 26(22):2738-45. PubMed ID: 18433946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses.
    Lichtenstein KA; Armon C; Nagabhushanam V; Efaw BJ; Frazer-Abel A; Hiserote ME; Alam R
    Antivir Ther; 2012; 17(7):1301-9. PubMed ID: 22948290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.